Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02889159 · ClinicalTrials.gov registry record · Phase 1

Immunologic Profile of Chronically Photodamaged Skin

A Phase 1 study, sponsored by University of Michigan.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT02889159 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02889159, a Phase 1 study, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

Chronically photodamaged skin is visually characterized by dryness, wrinkles, brown spots, leathery appearance, etc. This happens as a result of excessive exposure to UV light from the sun. While the sun's exposure leaves the skin's surface visibly changed, the skin's unseen immune system may also be permanently altered as a result of the exposure, making it more likely to develop a variety of skin cancers and infections. This study will examine the lasting changes in the immune system of the skin caused by UV exposure. Investigators will stimulate different aspects of the skin's immune system by giving an injection of Candida Albicans (CANDIN®) and histamine phosphate (HISTATROL®), topical applications of imiquimod 5% cream (ALDARA®) and performing a tape stripping procedure with adhesive tape. The use of Candida Albicans (CANDIN®), histamine phosphate (HISTATROL®), and tape stripping are common procedures in clinical settings to stimulate skin desired skin responses. Imiquimod 5% cream (ALDARA®) is an FDA-approved drug for the treatment of basal cell carcinomas, actinic keratoses and genital warts. Investigators will compare the reaction of the skin's immune system on a cellular level from skin normally exposed to the sun exposure to an area normally hidden from sun exposure.

Interventions

  • BIOLOGICAL Candida albicans antigen
  • BIOLOGICAL histamine phosphate
  • BIOLOGICAL imiquimod 5% cream
  • PROCEDURE Tape Stripping

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2016-06-06
Est. Completion 2023-02-23
Phase Phase 1

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT02889159

The ClinicalTrials.gov registry entry for NCT02889159 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Candida albicans antigen is the first listed.

NCT02889159 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02889159 about?

NCT02889159 is a clinical study titled "Immunologic Profile of Chronically Photodamaged Skin". Chronically photodamaged skin is visually characterized by dryness, wrinkles, brown spots, leathery appearance, etc. This happens as a result of excessive exposure to UV light from the sun. While the sun's exposure leaves the skin's surface visibly changed, the skin's unseen immune system may also b...

What is the current status of trial NCT02889159?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-06-06. Estimated completion is 2023-02-23.

What interventions are being tested in trial NCT02889159?

The interventions under investigation include: Candida albicans antigen (BIOLOGICAL), histamine phosphate (BIOLOGICAL), imiquimod 5% cream (BIOLOGICAL), Tape Stripping (PROCEDURE).

Who is sponsoring clinical trial NCT02889159?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.